Cooper Companies COO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Cooper Companies (COO) Business Model and Operations Summary
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
Key Insights
Cooper Companies (COO) Core Market Data and Business Metrics
Latest Closing Price
$81.27Market Cap
$16.22 BillionAverage Daily Trade Volume
1,818,359 SharesPrice-Earnings Ratio
-0.05Total Outstanding Shares
199.16 Million SharesCEO
Mr. Albert G. White IIITotal Employees
15,000Dividend
$0.03 Per Share BiannuallyIPO Date
December 6, 1983SIC Description
Ophthalmic GoodsPrimary Exchange
NASDAQHeadquarters
6101 Bollinger Canyon Road, San Ramon, CA, 94583
Historical Stock Splits
If you bought 1 share of COO before February 20, 2024, you'd have 4 shares today.
| Execution Date | Split Amount |
|---|---|
| February 20, 2024 | 4-for-1 |
Income Statement
November 1, 2024 to February 1, 2025
| Metric | Value |
|---|---|
| Net Income/Loss | $-38.17 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-38.17 Million |
| Benefits Costs and Expenses | $0 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Diluted Earnings Per Share | $-800 |
| Income/Loss From Continuing Operations Before Tax | $713.57 Million |
Comprehensive Income
November 1, 2024 to February 1, 2025
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-38.17 Million |
| Comprehensive Income/Loss | $-38.17 Million |
| Other Comprehensive Income/Loss | $0 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
November 1, 2024 to February 1, 2025
| Metric | Value |
|---|---|
| Equity | $278.49 Million |
| Wages | $16.97 Million |
| Inventory | $599.75 Million |
| Other Non-current Assets | $981.56 Million |
| Temporary Equity Attributable To Parent | $3.28 Million |
| Other Non-current Liabilities | $652.81 Million |
Historical Dividends
Current dividend: $0.03 Per Share Biannually
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Jul 12, 2023 | Aug 11, 2023 | Jul 27, 2023 | $0.03 | Biannually |
| Dec 14, 2022 | Feb 10, 2023 | Jan 23, 2023 | $0.03 | Biannually |
| Jul 13, 2022 | Aug 11, 2022 | Jul 27, 2022 | $0.03 | Biannually |
| Dec 8, 2021 | Feb 9, 2022 | Jan 21, 2022 | $0.03 | Biannually |
| Jul 14, 2021 | Aug 11, 2021 | Jul 27, 2021 | $0.03 | Biannually |
| Jan 7, 2021 | Feb 9, 2021 | Jan 22, 2021 | $0.03 | Biannually |